JP2007532685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532685A5 JP2007532685A5 JP2007508646A JP2007508646A JP2007532685A5 JP 2007532685 A5 JP2007532685 A5 JP 2007532685A5 JP 2007508646 A JP2007508646 A JP 2007508646A JP 2007508646 A JP2007508646 A JP 2007508646A JP 2007532685 A5 JP2007532685 A5 JP 2007532685A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pathological condition
- antagonist
- egfl7
- angiogenic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001575 pathological effect Effects 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 7
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 6
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 claims 5
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000010595 endothelial cell migration Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000010232 migration assay Methods 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56205404P | 2004-04-14 | 2004-04-14 | |
| US60/562,054 | 2004-04-14 | ||
| PCT/US2005/013658 WO2005117968A2 (en) | 2004-04-14 | 2005-04-14 | Compositions and methods comprising an egfl7 antagonist for modulating vascular development |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011190733A Division JP2011241230A (ja) | 2004-04-14 | 2011-09-01 | 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007532685A JP2007532685A (ja) | 2007-11-15 |
| JP2007532685A5 true JP2007532685A5 (enExample) | 2008-05-29 |
| JP5599136B2 JP5599136B2 (ja) | 2014-10-01 |
Family
ID=35355481
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007508646A Expired - Fee Related JP5599136B2 (ja) | 2004-04-14 | 2005-04-14 | 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物 |
| JP2011190733A Withdrawn JP2011241230A (ja) | 2004-04-14 | 2011-09-01 | 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法 |
| JP2013196507A Withdrawn JP2013256535A (ja) | 2004-04-14 | 2013-09-24 | 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011190733A Withdrawn JP2011241230A (ja) | 2004-04-14 | 2011-09-01 | 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法 |
| JP2013196507A Withdrawn JP2013256535A (ja) | 2004-04-14 | 2013-09-24 | 血管の発達を調節するための、ｅｇｆｌ７アンタゴニストを含む組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20070031437A1 (enExample) |
| EP (1) | EP1734998A2 (enExample) |
| JP (3) | JP5599136B2 (enExample) |
| KR (1) | KR101227817B1 (enExample) |
| CN (2) | CN1997394B (enExample) |
| AU (1) | AU2005249377A1 (enExample) |
| BR (1) | BRPI0509420A (enExample) |
| CA (1) | CA2563445C (enExample) |
| IL (2) | IL178329A0 (enExample) |
| MX (1) | MXPA06011851A (enExample) |
| NZ (1) | NZ550110A (enExample) |
| RU (3) | RU2365382C2 (enExample) |
| WO (1) | WO2005117968A2 (enExample) |
| ZA (1) | ZA200608615B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1734998A2 (en) | 2004-04-14 | 2006-12-27 | Genentech, Inc. | Compositions and methods comprising an egfl7 antagonist for modulating vascular development |
| AR059851A1 (es) * | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
| NZ573622A (en) | 2006-06-12 | 2011-12-22 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
| WO2008010986A2 (en) * | 2006-07-17 | 2008-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of modulating angiogenesis |
| US20090074761A1 (en) * | 2007-04-24 | 2009-03-19 | Jun Yan | Therapeutic beta-glucan combinations |
| JP2009005584A (ja) * | 2007-06-26 | 2009-01-15 | Miyazaki Prefecture | ゲル化剤、凍結保存剤、細胞保存用容器、細胞の凍結保存方法、細胞の融解方法、哺乳動物の細胞 |
| US9549971B2 (en) * | 2008-01-14 | 2017-01-24 | Genentech, Inc. | Methods for inhibiting angiogenesis using EGFL8 antagonists |
| WO2010034155A1 (zh) * | 2008-09-25 | 2010-04-01 | 中南大学湘雅医院 | 一种通过检测样品中eglf7来诊断肝细胞癌的试剂盒 |
| WO2010129904A1 (en) * | 2009-05-08 | 2010-11-11 | Genentech, Inc. | Humanized anti-egfl7 antibodies and methods using same |
| RU2412251C1 (ru) * | 2009-06-15 | 2011-02-20 | Юрий Леонидович Дорохов | Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении |
| CA2766403A1 (en) * | 2009-07-13 | 2011-01-20 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| ES2765657T3 (es) * | 2009-12-21 | 2020-06-10 | Hoffmann La Roche | Formulación farmacéutica de bevacizumab |
| WO2013061112A1 (en) | 2011-10-24 | 2013-05-02 | Centre National De La Recherche Scientifique | Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium |
| WO2013142961A1 (en) * | 2012-03-27 | 2013-10-03 | London Health Sciences Centre Research Inc. | Egfl7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis |
| WO2015077643A2 (en) * | 2013-11-21 | 2015-05-28 | Mfr Products, Inc. | Therapeutic device to assist in myofascial release, and method of use |
| CN107108711B (zh) * | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| CN105543183B (zh) * | 2016-01-08 | 2019-04-12 | 吴帆 | 人肝癌细胞Egfl8基因过表达慢病毒在制备治疗肝癌药物中的应用 |
| CA3061505A1 (en) | 2017-04-24 | 2018-11-01 | Ohio State Innovation Foundation | Recombinant egfl7, egfl7 antibodies, and uses thereof |
| RU2678200C1 (ru) * | 2018-07-27 | 2019-01-24 | Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" | Лекарственная пленка пролонгированного действия и способ её получения |
| WO2022025783A1 (ru) | 2020-07-28 | 2022-02-03 | Общество с ограниченной ответственностью "Ангиолайф" | Применения комбинации генов ангиогенных и нейротрофических факторов |
| CN114410642B (zh) * | 2021-12-31 | 2023-01-17 | 苏州大学 | 一种急性t淋巴细胞白血病药物靶点及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU597323B2 (en) * | 1985-11-22 | 1990-05-31 | Teijin Limited | Angiogenic factor derived from blood vessel endothelial cells |
| EP0318488A4 (en) | 1986-08-18 | 1990-02-26 | Biota Scient Management | STIMULATION OF ANGIOGENESIS AND PROMOTION OF ENDOTHELIALIZATION. |
| SK163598A3 (en) * | 1996-05-31 | 1999-06-11 | Scripps Research Inst | Methods and compositions useful for inhibition of angiogenesis |
| WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO1998057983A2 (en) * | 1997-06-18 | 1998-12-23 | Zymogenetics, Inc. | Mammalian neuro-growth factor like protein |
| US20030166907A1 (en) * | 1997-06-18 | 2003-09-04 | Zymogenetics, Inc. | Mammalian neuro-growth factor like protein |
| US5972338A (en) | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
| US20030166107A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| US7105640B2 (en) | 1997-10-17 | 2006-09-12 | Genentech, Inc. | Anti-pro792 antibodies |
| US20030069178A1 (en) | 1997-10-17 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030050240A1 (en) | 1997-10-17 | 2003-03-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6974696B2 (en) | 1997-10-17 | 2005-12-13 | Genentech, Inc. | PRO853 nucleic acids |
| US20030039648A1 (en) | 1998-09-16 | 2003-02-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| DK1490386T3 (da) | 1998-03-10 | 2008-12-15 | Genentech Inc | Nyt polypeptid og nukleinsyrer kodende for dette |
| US7371836B2 (en) | 1998-03-27 | 2008-05-13 | Genentech, Inc. | PRO526 nucleic acids |
| US7202338B2 (en) | 1998-03-31 | 2007-04-10 | Genentech, Inc. | PRO731 polypeptides |
| US7196176B2 (en) | 1998-04-01 | 2007-03-27 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6962797B2 (en) | 1998-04-15 | 2005-11-08 | Genentech, Inc. | Nucleic acids encoding PRO615 |
| DE19817946A1 (de) | 1998-04-17 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe |
| AU3965799A (en) | 1998-04-23 | 1999-11-08 | Millennium Pharmaceuticals, Inc. | Novel molecules of the t125-related protein family and uses thereof |
| US7067636B2 (en) | 1998-05-06 | 2006-06-27 | Genentech, Inc. | Anti-pro 1017 antibodies |
| US7279553B2 (en) | 1998-05-13 | 2007-10-09 | Genentech, Inc. | PRO1083 polypeptides |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| US7019115B2 (en) | 1998-05-22 | 2006-03-28 | Genentech, Inc. | Pro1017 polypeptides |
| US7220835B2 (en) | 1998-07-30 | 2007-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030203446A1 (en) | 1998-10-07 | 2003-10-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2000034477A2 (en) | 1998-12-11 | 2000-06-15 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| AU2596700A (en) | 1999-03-08 | 2000-09-28 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| US7109292B2 (en) | 1999-03-08 | 2006-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2004507202A (ja) | 1999-03-31 | 2004-03-11 | キュラジェン コーポレイション | ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」 |
| KR100427563B1 (ko) | 1999-04-16 | 2004-04-27 | 가부시키가이샤 후지킨 | 병렬분류형 유체공급장치와, 이것에 사용하는 유체가변형압력식 유량제어방법 및 유체가변형 압력식 유량제어장치 |
| US7214656B2 (en) | 1999-04-28 | 2007-05-08 | Genentech, Inc. | PRO792 polypeptides |
| EP1196561A2 (en) | 1999-07-02 | 2002-04-17 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| US20030119113A1 (en) | 1999-07-20 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| TWI265167B (en) | 1999-11-29 | 2006-11-01 | Akzo Nobel Nv | 3-methylene steroid derivatives |
| AU2001233041A1 (en) | 2000-01-25 | 2001-08-07 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US7265210B2 (en) | 2000-09-15 | 2007-09-04 | Genentech, Inc. | Anti-PRO9821 antibodies |
| ES2252461T3 (es) * | 2001-02-05 | 2006-05-16 | Innoventus Project Ab | Glicoproteina rica en histidina (hrgp) para la inhibicion de la angiogenesis. |
| US20030224984A1 (en) * | 2001-06-20 | 2003-12-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20030119112A1 (en) | 2001-06-20 | 2003-06-26 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US7202335B2 (en) | 2001-12-06 | 2007-04-10 | Genentech, Inc. | PRO300 polypeptides |
| FR2851249A1 (fr) * | 2003-02-17 | 2004-08-20 | Commissariat Energie Atomique | Nouveau facteur soluble secrete par les cellules endotheliales des vaisseaux sanguins, capable d'inhiber le recrutement des cellules perivasculaires du type musculaire lisse et ses applications |
| EP1734998A2 (en) | 2004-04-14 | 2006-12-27 | Genentech, Inc. | Compositions and methods comprising an egfl7 antagonist for modulating vascular development |
-
2005
- 2005-04-14 EP EP05804788A patent/EP1734998A2/en not_active Ceased
- 2005-04-14 NZ NZ550110A patent/NZ550110A/en not_active IP Right Cessation
- 2005-04-14 MX MXPA06011851A patent/MXPA06011851A/es active IP Right Grant
- 2005-04-14 CN CN2005800195117A patent/CN1997394B/zh not_active Expired - Fee Related
- 2005-04-14 BR BRPI0509420-8A patent/BRPI0509420A/pt not_active IP Right Cessation
- 2005-04-14 WO PCT/US2005/013658 patent/WO2005117968A2/en not_active Ceased
- 2005-04-14 KR KR1020067021268A patent/KR101227817B1/ko not_active Expired - Fee Related
- 2005-04-14 JP JP2007508646A patent/JP5599136B2/ja not_active Expired - Fee Related
- 2005-04-14 CA CA2563445A patent/CA2563445C/en not_active Expired - Fee Related
- 2005-04-14 ZA ZA200608615A patent/ZA200608615B/en unknown
- 2005-04-14 CN CN2012103813601A patent/CN102895663A/zh active Pending
- 2005-04-14 RU RU2006140081/13A patent/RU2365382C2/ru not_active IP Right Cessation
- 2005-04-14 AU AU2005249377A patent/AU2005249377A1/en not_active Abandoned
-
2006
- 2006-09-27 IL IL178329A patent/IL178329A0/en active IP Right Grant
- 2006-10-12 US US11/546,760 patent/US20070031437A1/en not_active Abandoned
-
2009
- 2009-01-22 US US12/357,819 patent/US20090297512A1/en not_active Abandoned
- 2009-04-16 RU RU2009114508/15A patent/RU2009114508A/ru unknown
-
2010
- 2010-10-14 US US12/904,813 patent/US8790646B2/en not_active Expired - Fee Related
-
2011
- 2011-09-01 JP JP2011190733A patent/JP2011241230A/ja not_active Withdrawn
-
2013
- 2013-06-13 IL IL226899A patent/IL226899A0/en unknown
- 2013-09-24 JP JP2013196507A patent/JP2013256535A/ja not_active Withdrawn
- 2013-10-16 RU RU2013146239/15A patent/RU2013146239A/ru not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532685A5 (enExample) | ||
| RU2006140081A (ru) | Композиции и способы для регуляции развития сосудов | |
| JP2013527189A5 (enExample) | ||
| EP2019830A4 (en) | INHIBITORS OF THE SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR THE TREATMENT OF A CHRONIC HEPATITIS VIRUS | |
| JP2007522094A5 (enExample) | ||
| CN112368281A (zh) | 作为pde3/pde4双重抑制剂的三并环类化合物 | |
| JP2010285439A5 (enExample) | ||
| JP2008513467A5 (enExample) | ||
| NO332405B1 (no) | Forbindelse av 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling, deres anvendelse til fremstilling av farmasoytiske midler for behandling av inflammatorisk sykdom og farmasoytisk preparat omfattende forbindelsen. | |
| ATE516285T1 (de) | Dihydropyridinonderivate | |
| JP2014012726A5 (enExample) | ||
| JP2010120964A5 (enExample) | ||
| JP2007526455A5 (enExample) | ||
| ATE447568T1 (de) | Neue pyrinderivate | |
| JP2017523985A5 (enExample) | ||
| JP2010222367A5 (enExample) | ||
| JP2014512396A5 (enExample) | ||
| JP2012046518A5 (enExample) | ||
| JP2014513036A5 (enExample) | ||
| JP2019520550A5 (enExample) | ||
| JP2011522816A5 (enExample) | ||
| JP2008527066A5 (enExample) | ||
| MA29097B1 (fr) | Composes pour le traitement des infections virales par flaviviridae | |
| JP2017530163A5 (enExample) | ||
| JP2009538898A5 (enExample) |